Mimetas B.V.

Mimetas B. V. is a biotechnology firm focused on developing advanced human tissue models to streamline drug discovery and development processes, primarily for the pharmaceutical and biopharmaceutical industries. Founded in 2013 in Leiden, Netherlands, Mimetas B.

V. develops 3D tissue models for drug discovery. The company's founders, Jos Joore, Paul Vulto, and Thomas Hankemeier, have extensive backgrounds in biotechnology. Mimetas has completed 6 deals, with the most recent funding round being a GRANT of EUR 3.

00 mn raised in June 2020 from EASME. The total amount raised by the company amounts to EUR 20. 50 mn. Mimetas specializes in advanced human tissue models that enhance drug discovery and development processes.

Their flagship product, the OrganoPlate®, utilizes a proprietary platform to create robust assays for various therapeutic areas, including cancer and immunology. The company offers tailored partnerships and fee-for-service solutions for pharmaceutical and biotechnology clients, focusing on optimizing compounds and de-risking drug development. Mimetas generates revenue through a fee-for-service model, providing customized solutions to clients in the pharmaceutical and biotech sectors. The company engages in business-to-business transactions, with clients paying for the use of their OrganoReady program, which offers optimized assays for investigational toxicology.

The revenue streams are supported by collaborations with industry leaders, with EBITDA for the most recent year reaching EUR 224,106. 60. Mimetas plans to launch new products tailored to meet the evolving needs of drug discovery, with specific details on release dates yet to be disclosed. The company aims to expand its market presence in North America and Europe, targeting these regions with their innovative tissue models.

The recent funding round, which raised EUR 3. 00 mn, will be utilized to support these initiatives, enhancing their capabilities in providing specialized solutions for preclinical research.